Hologic, Inc. revised earnings guidance for the Fiscal year 2024. For the year, the Company expects revenues of $3,990 million to $4,065 million compared to previous guidance of $3,920 million to $4,020 million and GAAP EPS of $3.52 to $3.67 compared to previous guidance of $3.19 to $3.39.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.81 USD | +1.69% | +0.01% | +3.30% |
May. 29 | Transcript : Hologic, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 10:00 AM | |
May. 22 | FDA classifies recall of Hologic's implant as 'most serious' | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.30% | 17.23B | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.61B |
- Stock Market
- Equities
- HOLX Stock
- News Hologic, Inc.
- Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024